- Home
- HHS vs RFL Comparison
HHS vs RFL Comparison
Compare HHS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- RFL
- Stock Information
- Founded
- HHS 1923
- RFL 2017
- Country
- HHS United States
- RFL United States
- Employees
- HHS N/A
- RFL N/A
- Industry
- HHS Advertising
- RFL Real Estate
- Sector
- HHS Consumer Discretionary
- RFL Finance
- Exchange
- HHS Nasdaq
- RFL Nasdaq
- Market Cap
- HHS 39.4M
- RFL 55.3M
- IPO Year
- HHS N/A
- RFL N/A
- Fundamental
- Price
- HHS $5.25
- RFL $1.50
- Analyst Decision
- HHS
- RFL
- Analyst Count
- HHS 0
- RFL 0
- Target Price
- HHS N/A
- RFL N/A
- AVG Volume (30 Days)
- HHS 21.5K
- RFL 35.4K
- Earning Date
- HHS 11-14-2024
- RFL 12-11-2024
- Dividend Yield
- HHS N/A
- RFL N/A
- EPS Growth
- HHS N/A
- RFL N/A
- EPS
- HHS N/A
- RFL N/A
- Revenue
- HHS $187,604,000.00
- RFL $697,000.00
- Revenue This Year
- HHS N/A
- RFL N/A
- Revenue Next Year
- HHS $4.05
- RFL N/A
- P/E Ratio
- HHS N/A
- RFL N/A
- Revenue Growth
- HHS N/A
- RFL 151.62
- 52 Week Low
- HHS $5.25
- RFL $1.29
- 52 Week High
- HHS $8.87
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- HHS 35.21
- RFL 35.59
- Support Level
- HHS $5.25
- RFL $1.52
- Resistance Level
- HHS $5.59
- RFL $1.96
- Average True Range (ATR)
- HHS 0.21
- RFL 0.13
- MACD
- HHS 0.02
- RFL -0.03
- Stochastic Oscillator
- HHS 18.48
- RFL 12.50
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.